p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide

American Journal of Clinical Pathology

Volumn 137, Issue 2, 2012, Pages 208-212

  Chen, Mei Hsi ^a,b   Qi, Connie X Y ^a,b   Saha, Manujendra N ^a,b   Chang, Hong ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

del(17p13); FISH; Fluorescence in situ hybridization; Immunohistochemistry; Lenalidomide; p53

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; PROTEIN P53; THALIDOMIDE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER RELAPSE; CELL NUCLEUS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HEMIZYGOSITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CANADA; CELL NUCLEUS; CHROMOSOMES, HUMAN, PAIR 17; DEXAMETHASONE; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; GENE DELETION; HEMIZYGOTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECURRENCE; SURVIVAL RATE; THALIDOMIDE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863065064     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPHC85DGAXZDBE     Document Type: Article

References (21)

1. Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24(suppl 1):S13-S19.
2. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-2132. (Pubitemid 350146107)
3. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-2142. (Pubitemid 350146108)
4. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114:522-525.
5. Dimopoulos MA, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010;24:1769-1778.
6. Klein U, Jauch A, Hielscher T, et al. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer. 2011;117:2136-2144.
7. Kapoor R, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009;114:518-521.
8. Chang H, Yeung J, Qi C, et al. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous p53 deletion and poor survival for multiple myeloma. Br J Haematol. 2007;138:324-329. (Pubitemid 47035385)
9. Chang H, Li D, Zhuang L, et al. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leuk Lymphoma. 2004;45:965-969. (Pubitemid 38444673)
10. Chang H, Yeung J, Xu W, et al. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukemia as demonstrated by interphase fluorescence in situ hybridisation. Br J Haematol. 2006;134:613-615. (Pubitemid 44253603)
11. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520.
12. Lepelley P, Preudhomme C, Vanrumbeke M, et al. Detection of p53 mutations in haematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia. 1994;8:1342-1349. (Pubitemid 24262491)
13. Nigro JM, Bigner SH, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705-708. (Pubitemid 20001591)
14. Levine AJ, Momand J, Finay CA. The p53 tumor suppressor gene. Nature. 1991;351:453-456.
15. Chng WJ, Price-Troska T, Gonzalez-Paz N, et al. Clinical significance of TP53 mutation in myeloma [letter]. Leukemia. 2007;21:582-584.
16. Lode L, Eveillard M, Trichet V, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95:1973-1976.
17. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev. 2003;13:77-83. (Pubitemid 36143931)
18. Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010;18:367-381.
19. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878. (Pubitemid 24289415)
20. Kelley TW, Baz R, Hussein M, et al. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen. Hum Pathol. 2009;40:405-412.
21. Dawson MA, Opat SS, Taouk Y, et al. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin Cancer Res. 2009;15:714-722.